

Translational Basic Research		
<b>Antitubercular Nonribosomal Peptides</b> Oregon State Univ, NIH	<b>Identification of compounds inhibiting pantothenate synthase (PanC) –</b> NIH, NIAID, UCLA	<b>Identification and validation of targets for TB persistence</b> Seattle Biomedical Research Institute, BMGF
<b>Inhibitors for persistence targets</b> NIH, Texas A&M	<b>Inhibitors of menaquinone biosynthesis</b> Stony Brook, Colorado State Univ, NIH, MSKCC	<b>Metabolic modeling of <i>M. tuberculosis</i></b> – Univ Surrey, Biotechnology and Biological Sciences Research Council
<b>Novel targets for treatment of latent TB</b> – Imperial College London, BMGF, Wellcome Trust	<b>Sterol Metabolism of <i>M. tuberculosis</i></b> Stony Brook, PHRI	<b>Thymidylate Synthases as Drug Targets</b> Univ Washington, NIH
Discovery		
<b>b-Sulfonylcarboxamides</b> Johns Hopkins Univ, NIH	<b>Cell Wall Biosynthesis Inhibitors (1)</b> Univs Birmingham, Strathclyde, Montpellier, Texas A&M, SRI, Wellcome Trust <b>(2)</b> Colorado State Univ, St Andrews Univ, Univ Tennessee Memphis	
<b>Dihydrolipoamide Acyltransferase Inhibitors</b> Cornell Univ, NIAID	<b>Diphenyl ether based inhibitors of FabI (InhA)</b> Stony Brook, NIH, NIAID, CSU, NJMRC, Univ Wurzburg	<b>Energy Metabolism</b> GlaxoSmithKline, TB Alliance
<b>FtsZ Inhibitors</b> Stony Brook, Colorado State Univ, SRI	<b>Indole derivatives</b> Colorado State Univ, NIH, INEOS Moscow	<b>InhA Inhibitors</b> GlaxoSmithKline, TB Alliance
<b>Lilly Not-for-Profit Partnership for TB Early Phase Drug Discovery</b> – Eli Lilly & Co., IDRI, NIAID	<b>Malate Synthase Inhibitors</b> – GlaxoSmithKline, Rockefeller Univ, Texas A&M, TB Alliance	<b>Multi-Functional Molecules</b> Cumbre, TB Alliance, Colorado State Univ
<b>Mycobacterial Sulfation Pathway Inhibitors</b> Univ California Berkeley, NIH	<b>Mycobacterial Gyrase Inhibitors</b> GlaxoSmithKline, TB Alliance	<b>Mycobacterial Siderophore Biosynthesis Inhibitors</b> CDD at Univ Minnesota, NIAID, NIH
<b>Natural Products Exploration (1)</b> NERC Centre, Univ Strathclyde, Univ Illinois Chicago <b>(2)</b> Georgia Institute of Technology, NIH, Univ South Pacific <b>(3)</b> BIOTEC, California State Univ, ITR, NIAID, TAACF, Univ Auckland		<b>Nitroimidazole Analogs</b> TB Alliance, Univ Auckland
<b>Nitrofuranylamides</b> - NIH, NIAID, Univ Tennessee Health Science Centre, Colorado State Univ	<b>NM4TB Discovery Portfolio</b> AstraZeneca, European Commission	<b>Novartis Portfolio</b> Novartis
<b>Oxazolidinones</b> Pfizer Inc	<b>Peptide Deformylase Inhibitors</b> GlaxoSmithKline, TB Alliance	<b>Pleuromutilins</b> GlaxoSmithKline, TB Alliance
<b>Phenotypic Whole Cell Screening</b> <b>(1)</b> Univ Illinois Chicago, TB Alliance <b>(2)</b> NIH, NIAID, TAACF <b>(3)</b> AstraZeneca		<b>Promazine Analogs</b> Salisbury University
<b>Protease Inhibitors</b> IDRI	<b>Proteasome Inhibitors</b> Cornell Univ, NIAID	<b>Quinolones</b> KRICT, Yonsei Univ, TB Alliance
<b>Riminophenazines</b> – Institute of Materia Medica, BTTTRI, TB Alliance	<b>Sanofi-Aventis Portfolio</b> Sanofi-Aventis	<b>Small molecule inhibitors of validated targets</b> Seattle Biomedical Research Institute, BMGF
<b>Target-based screening, Lead Optimization</b> AstraZeneca	<b>Type-II NADH-menaquinone oxidoreductase Inhibitors</b> – Univ Pennsylvania, Univ Illinois Chicago, NIH	
Preclinical		
<b>Dipiperidine SQ-609</b> Sequella Inc.	<b>Gyrase Inhibitor</b> Pharma	<b>Compounds with <i>in vivo</i> activity against <i>M. tuberculosis</i> in animal models</b> – NIH, NIAID, Colorado State Univ
<b>Nitroimidazole Backup Compound</b> Otsuka Pharmaceutical Co.	<b>Non-Fluorinated Quinolone</b> TaiGen	<b>Oxazolidinones</b> Pharma
<b>Synthase Inhibitor FAS20013</b> FASgen Inc.	<b>Translocase I Inhibitors</b> Sequella Inc., Sankyo	
Clinical		
<b>Capreomycin for Inhalation</b> MEND, NIAID, BMGF	<b>Diamine SQ-109</b> Sequella Inc.	<b>Diarylquinoline TMC207</b> Tibotec Pharmaceuticals Limited
<b>Gatifloxacin</b> – OFLOTUB Consortium: Lupin, NIAID TBRU, Tuberculosis Research Centre, WHO TDR	<b>Levofloxacin</b> DMID/NIAID/NIH, TBRU	<b>Linezolid</b> <b>(1)</b> DMID/NIAID/NIH, TBRU <b>(2)</b> CDC TBTC, Pfizer
<b>Metronidazole for Latent Infection</b> Imperial College London, BMGF, Wellcome Trust	<b>Moxifloxacin (1)</b> Bayer, CDC TBTC, Johns Hopkins Univ, TB Alliance <b>(2)</b> DMID/NIAID/NIH, TBRU	<b>Nitroimidazole PA-824</b> TB Alliance
<b>Nitrodihydro-imidazooxazole Derivative OPC-67683</b> Otsuka Pharmaceutical Co.	<b>Pyrrrole LL-3858 (Sudoterb)</b> Lupin Limited	<b>Rifapentine</b> Sanofi-Aventis, TBTC (treatment), Johns Hopkins Univ/NIAID (prophylaxis)
<b>Vitamin D</b> Christian Medical College Vellore, Dalhousie University	<b>High Dose Rifampicin</b> - St George's Univ Inter TB, Nijmegen Medical Centre, Harvard Medical School, NIH	